Research - Polycystic kidney disease | PKD treatment research

Since the Foundation’s establishment in 1982, it has invested nearly $30 million in dedicated PKD research, clinical and scientific grant awards, fellowships, and scientific meetings.

The Foundation’s financial commitment over the years has seen results on a local, national, and even global level. This includes implementing funding opportunities for emerging investigators, support for innovation, and leveraging funding from prestigious institutions such as the National Institutes of Health and Department of Defense.

Our research team also launched the nation’s largest patient-powered ADPKD Registry and routinely convenes research stakeholders in the PKD Outcomes Consortium. In 2022, the Foundation launched the PKD Centers of Excellence program to ensure access to PKD-specialized care and accelerate the translation of research studies to the clinic.

Together, these programs span from pre-clinical basic science to clinical trials to maximize efforts towards our goal of ending PKD.

ANCHOR ADPKD Study

The ANCHOR ADPKD study, sponsored by Calico Life Sciences, is a Phase 2 clinical research study evaluating the safety and efficacy of an investigational medication in adults with autosomal dominant polycystic kidney disease (ADPKD).

To learn more or find a study site, visit: anchoradpkd.com

For questions, contact clinicaltrialcommunication@calicolabs.com

This investigational medication has not been approved by the FDA or any other regulatory authority, and its safety and efficacy have not been established.

Disclaimer: This research opportunity is being conducted by Calico. The PKD Foundation is sharing this information for awareness purposes only and does not endorse any specific company, product, or clinical trial. Participation is voluntary.